Answers are grounded in this paper and cite their sources.
The study aimed to determine the comparative efficacy of dexamethasone and methylprednisolone in treating severely ill COVID-19 patients in terms of mortality. Using a quasi-experimental design, the study was conducted at Mayo Hospital, Lahore, from May 2021 to October 2021. A total of 148 patients, divided into two groups of 74 each (groups A and B), were included in the study. Group A was given 6mg of dexamethasone, while group B was given methylprednisolone 40mg twice daily for 10 days. All the collected data was analyzed using SPSS 26.0, and Chi-square was used to find the mortality association between the two groups. A p-value of less than 0.05 was considered significant. The results showed that the age and gender distribution for the methylprednisolone and dexamethasone groups were 56.89±13.3 (M=36, F=38) and 57.69±12.6 (M=38, F=36), respectively. In terms of mortality, 45 patients died in the methylprednisolone group, while 54 people died in the dexamethasone group. There was statistical significance regarding mortality in both groups (p=0.003). In conclusion, the study found that administering 40mg of methylprednisolone twice daily produced better outcomes than 6mg of dexamethasone once daily in treating severe COVID-19 patients in the hospital.
No takes yet. Share an insight, caveat, or question.
HASHMI et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: